# EDGAR Filing Document

**Accession Number:** 0001810560
**File Stem:** 0001213900-23-008310
**Filing Date:** 2023-2
**Character Count:** 1880
**Document Hash:** 33d4a87408a54850b84a3b2f137d4dfb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-008310.hdr.sgml**: 20230310

**ACCESSION NUMBER**: 0001213900-23-008310

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230206

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** REVELATION BIOSCIENCES, INC.
- **CENTRAL INDEX KEY:** 0001810560
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 843898466
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 4660 LAJOLLA VILLAGE DRIVE
- **STREET 2:** SUITE 100
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92122
- **BUSINESS PHONE:** 650-800-3717

**MAIL ADDRESS:**
- **STREET 1:** 4660 LAJOLLA VILLAGE DRIVE
- **STREET 2:** SUITE 100
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92122

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Petra Acquisition Inc.
- **DATE OF NAME CHANGE:** 20200423

Revelation Biosciences, Inc.

4660 La Jolla Village Drive

San Diego, California 92122

 

February 6, 2023

 

*Via EDGAR*

Securities and Exchange Commission

100 F Street, NE

Washington, DC 20549

Attention: Daniel Crawford <br> Joe McCann

Re: Revelation Biosciences, Inc. <br> Registration Statement on Form S-1 <br> Commission File No. 333-268576

Messrs. Crawford and McCann:

On behalf of Revelation Biosciences, Inc. (the "Company"), I hereby request that the Commission declare effective the above-captioned registration statement at 5:00pm on February 8, 2023, or as soon thereafter as practicable. Please call or email our counsel, J.P. Galda, with any further questions or comments.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| Revelation Biosciences, Inc. | Revelation Biosciences, Inc. |
| /s/ | Chester S. Zygmont, III |
|  | Chief Financial Officer |

---